- ►aub.edu.lb [PDF] S Khosla, D Burr, J Cauley, DW Dempster, … - Journal of Bone and …, 2007 - Am Soc Bone Min Res Drs Koka, McGowan, Mohla, Ruggiero, and Shum state that they have no conflicts of
interest. The conflicts for Drs Khosla, Shane, Burr, Cauley, Dempster, Ebeling, Felsenberg,
Gagel, Guise, McCauley, McKee, Pendrys, Raisz, Shafer, Silverman, Van Poznak, Watts, ... Cited by 180 - Related articles - All 10 versions
- ►einstein.br [PDF] DM Black, AV Schwartz, KE Ensrud, JA Cauley, S Levis … - Jama, 2006 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do to make
your experience on this site better. ... Context The optimal duration of treatment of women ... Cited by 167 - Related articles - BL Direct - All 9 versions
- ►hyperbaricinformation.com [PDF] JP Bilezikian - New England Journal of Medicine, 2006 - content.nejm.org N itrogen-containing bisphos- phonates are used widely for the management of metastatic cancer
in bone (intravenous zole- dronic acid or pamidronate), for the prevention and treatment of osteoporosis
(oral alendronate, risedronate, and ibandronate and intravenous ibandronate), for the ... Cited by 122 - Related articles - BL Direct - All 10 versions
- ►jcojournal.org MD Michaelson, DS Kaufman, H Lee, FJ … - Journal of Clinical …, 2007 - jcojournal.org Results Mean (± SE) BMD of the posteroanterior lumbar spine decreased by 3.1% ± 1.0% in
men assigned to placebo and increased by 4.0% ± 1.0% in men assigned to zoledronic acid
(P < .001). BMD of the total hip decreased by 1.9% ± 0.7% in men assigned to placebo ... Cited by 61 - Related articles - All 8 versions
- ►nih.gov AO Hoff, BB Toth, K Altundag, MM … - Journal of Bone and …, 2008 - Am Soc Bone Min Res Dr Gagel has served as a speaker and received research support from Novartis
Pharmaceuticals. Drs Hortobagyi and Hoff received research support from Novartis
Pharmaceuticals. All other authors state that they have no conflicts of interest. Cited by 60 - Related articles - All 7 versions
- ►ascopubs.org D Crivellari, M Aapro, R Leonard, G von … - Journal of Clinical …, 2007 - jco.ascopubs.org Screening and adjuvant postoperative therapies have increased survival among women with
breast cancer. These tools are seldom applied in elderly patients, although the usually reported
incidence of breast cancer is close to 50% in women 65 years or older, reaching 47% ... Cited by 55 - Related articles - All 6 versions
- ►osteoporosis.ca [PDF] E Shane, S Goldring, S Christakos, M … - Journal of Bone and …, 2006 - Am Soc Bone Min Res Dr Drezner receives research support from Eli Lilly & Co., Merck, and Roche. Dr Eisman receives
research support and/or provides consulting to Amgen, deCode, Eli Lilly & Co., GE-Lunar,
Merck, Sharpe & Dohme, Novartis, Organon, Pfizer, Roche-GSK, Sanofi-Avenits, and ... Cited by 50 - Related articles - BL Direct - All 6 versions
- ►hematologylibrary.org B Mehrotra, S Ruggiero - Hematology, 2006 - asheducationbook. … Bisphosphonate therapy has been incorporated in the standard management of patients with
multiple myeloma–related bony disease. Although their efficacy in reducing skeletal related events
is important in the supportive management of the myeloma patient, post-marketing ... Cited by 39 - Related articles - All 3 versions
PD Miller - Seminars in dialysis, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 33 - Related articles - BL Direct - All 4 versions
- ►oxfordjournals.org GS Wilkinson, YF Kuo, JL Freeman, JS … - JNCI Journal of the …, 2007 - jnci.oxfordjournals.org Methods: We identified 16073 cancer patients who were diagnosed between January 1,
1986, and December 31, 2002, and were treated intravenously with the bisphosphonates pamidronate
and/or zoledronic acid between January 1, 1995, and December 31, 2003. We matched ... Cited by 36 - Related articles - BL Direct - All 5 versions
